Lonza will add bioconjugate, payload-linker and viral vector capacity and about 1,100 employees; closing is expected in mid-2027.
News|Articles|November 3, 2026
The Four Pillars of Evidence Management for HEOR Teams
Author(s)Access Infinity
This guide equips HEOR, value and access leaders with the four pillars of modern evidence management: a living evidence library, intelligent curation, dynamic updating of the evidence package, and proactive evidence gap identification. It includes real-world examples of time and cost savings, and a quick self-assessment to see where your team stands.
Related to this article
Novartis exits its BrainTransporter deal with BioArctic 14 months after signing, citing an internal portfolio decision unrelated to the platform.
Teva will gain U.S. rights to two approved Samsung Bioepis biosimilars in a profit-sharing deal expected to close by the end of 2026.
Karyopharm filed for Chapter 11 under a plan to merge with Ayrmid, with competing bids allowed and closing targeted for the first quarter of 2027.
Dr. Jay Lalezari of CytoDyn explains why Leronlimab’s circulating tumor DNA results in colorectal cancer represent a unique, mechanism-specific proof of concept rather than a broader template.
FDA grants accelerated approval to INOVIO’s Voceryq to reduce surgical burden in recurrent respiratory papillomatosis, Brox.AI’s Hamish Brocklebank on the three levels of digital clone use cases in pharma, and CytoDyn’s Dr. Jay Lalezari on his path from HIV clinician to CEO.
PhRMA's Scott LaGanga discusses the expanding influence of state policymaking on drug pricing, PBM reform, and efforts to translate policy changes into lower out-of-pocket costs for patients.
FDA grants accelerated approval to INOVIO’s Voceryq for reducing surgery frequency in adults with recurrent respiratory papillomatosis.
Trending on PharmExec
1
What Does a Positive Reading for Leronlimab Mean for How the Industry Thinks About Repurposing Old Biologics Into Oncology?
2
States Take Center Stage in the Drug Pricing Fight
3
Karyopharm Enters Chapter 11 in Planned Merger With Ayrmid
4
Pharmaceutical Executive Daily: FDA Approves Voceryq
5